U.S. Acute External Ventricular Drain Market Size, Share, Trends, & Industry Analysis Report By Patient Type (Pediatric and Adult), By Application, and By Country

Description

List of Tables

The U.S. acute external ventricular drain market size is expected to reach USD 170.39 Million by 2034, according to a new study by Polaris Market Research. The report "US Acute External Ventricular Drain Market Size, Share, Trends, & Industry Analysis Report By Patient Type (Pediatric and Adult), By Application, and By Country - Market Forecast, 2025-2034" gives a detailed insight into current market dynamics and provides analysis on future market growth.

The US acute external ventricular drain (EVD) market is growing significantly as hospitals and trauma centers focus more on advanced brain care technologies. EVD systems are now considered an essential part of managing patients with brain injuries, helping doctors safely remove excess cerebrospinal fluid and reduce pressure in the brain. These systems are crucial in intensive care units, enabling timely and precise management of elevated intracranial pressure.

Companies in the US are developing smarter medical devices that are easier to use, reduce infection risks, and improve safety. The adoption of advanced EVD technologies across hospitals is increasing the demand for modern drainage systems. The growing involvement of neurosurgical teams and healthcare providers made these systems a critical part of emergency and critical care protocols, contributing to steady market growth across the country.

U.S. Acute External Ventricular Drain Market Report Highlights

Based on patient type, the adult segment dominated the market in 2024. This is attributed to the higher incidence of traumatic brain injuries, intracranial hemorrhages, and age-associated neurological disorders within this demographic.

In terms of application, the subarachnoid hemorrhage segment is projected to experience the highest growth rate in the coming years. This accelerated growth stems from cases involving aneurysmal ruptures and spontaneous bleeding into the subarachnoid space

A few global key market players include Abbott Laboratories, Anuncia Medical, Inc., B. Braun Medical Inc. (Aesculap, Inc.), Becton, Dickinson and Company, Boston Scientific Corporation, Fuji Systems USA, Inc., ICU Medical, Inc., Integra LifeSciences Corporation, Medtronic, Inc., Natus Medical Incorporated, Smiths Medical, Inc., Stryker Corporation, Teleflex Incorporated, Thermo Fisher Scientific Inc., and Zimmer Biomet Holdings, Inc.

Polaris Market Research has segmented the market report on the basis of patient type, application, and region:

By Patient Type Outlook (Revenue, USD Million, 2020-2034)

Pediatric

Adult

By Application Outlook (Revenue, USD Million, 2020-2034)

Traumatic Brain Injury

Subarachnoid Hemorrhage

Intracerebral Hemorrhage

Other Non-traumatic Hydrocephalus Conditions

Product Code: PM6005

1. Introduction

1.1. Report Description
- 1.1.1. Objectives of the Study
- 1.1.2. Market Scope
- 1.1.3. Assumptions
1.2. Stakeholders

2. Executive Summary

2.1. Market Highlights

3. Research Methodology

3.1. Overview
- 3.1.1. Data Mining
3.2. Data Sources
- 3.2.1. Primary Sources
- 3.2.2. Secondary Sources

4. US Acute External Ventricular Drain Market Insights

4.1. Acute External Ventricular Drain Market - Market Snapshot
4.2. Acute External Ventricular Drain Market Dynamics
- 4.2.1. Drivers and Opportunities
  - 4.2.1.1. High Incidence of Traumatic Brain Injuries (TBIs) is Supporting Market Growth
  - 4.2.1.2. Strong Presence of Key Market Players is Accelerating the Market Growth
- 4.2.2. Restraints and Challenges
  - 4.2.2.1. High Device and Procedure Costs
  - 4.2.2.2. Regulatory and Quality-Compliance Burden
4.3. Porter's Five Forces Analysis
- 4.3.1. Bargaining Power of Suppliers (Moderate)
- 4.3.2. Threats of New Entrants: (Low)
- 4.3.3. Bargaining Power of Buyers (Moderate)
- 4.3.4. Threat of Substitute (Moderate)
- 4.3.5. Rivalry among existing firms (High)
4.4. PESTEL Analysis
4.5. Acute External Ventricular Drain Market Trends
4.6. Value Chain Analysis

5. US Acute External Ventricular Drain Market, by Patient Type

5.1. Key Findings
5.2. Introduction
- 5.2.1. US Acute External Ventricular Drain Market, by Patient Type, 2020-2034 (USD Million)
5.3. Paediatric
- 5.3.1. US Acute External Ventricular Drain Market, by Paediatric, by Country, 2020-2034 (USD Million)
5.4. Adult
- 5.4.1. US Acute External Ventricular Drain Market, by Adult, by Country, 2020-2034 (USD Million)

6. US Acute External Ventricular Drain Market, by Application

6.1. Key Findings
6.2. Introduction
- 6.2.1. US Acute External Ventricular Drain Market, by Application, 2020-2034 (USD Million)
6.3. Traumatic Brain Injury
- 6.3.1. US Acute External Ventricular Drain Market, by Traumatic Brain Injury, by Country, 2020-2034 (USD Million)
6.4. Subarachnoid Haemorrhage
- 6.4.1. US Acute External Ventricular Drain Market, by Subarachnoid Haemorrhage, by Country, 2020-2034 (USD Million)
6.5. Intracerebral Hemorrhage
- 6.5.1. US Acute External Ventricular Drain Market, by Intracerebral Hemorrhage, by Country, 2020-2034 (USD Million)
6.6. Other Non-traumatic Hydrocephalus Conditions
- 6.6.1. US Acute External Ventricular Drain Market, by Other Non-traumatic Hydrocephalus Conditions, by Country, 2020-2034 (USD Million)

7. US Acute External Ventricular Drain Market, by Country

7.1. Key Findings
7.2. Introduction
- 7.2.1. Acute External Ventricular Drain Market Assessment, By Country, 2020-2034 (USD Million)
7.3. Acute External Ventricular Drain Market - US
- 7.3.1. US: Acute External Ventricular Drain Market, by Patient Type, 2020-2034 (USD Million)
- 7.3.2. US: Acute External Ventricular Drain Market, by Application, 2020-2034 (USD Million)

8. Competitive Landscape

8.1. Expansion and Acquisition Analysis
- 8.1.1. Expansion
- 8.1.2. Acquisitions
8.2. Partnerships/Collaborations/Agreements/Exhibitions

9. Company Profiles

9.1. Abbott Laboratories
- 9.1.1. Company Overview
- 9.1.2. Financial Performance
- 9.1.3. Product Benchmarking
- 9.1.4. Recent Development
9.2. Anuncia Medical, Inc.
- 9.2.1. Company Overview
- 9.2.2. Financial Performance
- 9.2.3. Product Benchmarking
- 9.2.4. Recent Development
9.3. B. Braun Medical Inc. (Aesculap, Inc.)
- 9.3.1. Company Overview
- 9.3.2. Financial Performance
- 9.3.3. Product Benchmarking
- 9.3.4. Recent Development
9.4. Becton, Dickinson and Company
- 9.4.1. Company Overview
- 9.4.2. Financial Performance
- 9.4.3. Product Benchmarking
- 9.4.4. Recent Development
9.5. Boston Scientific Corporation
- 9.5.1. Company Overview
- 9.5.2. Financial Performance
- 9.5.3. Product Benchmarking
- 9.5.4. Recent Development
9.6. Fuji Systems USA, Inc.
- 9.6.1. Company Overview
- 9.6.2. Financial Performance
- 9.6.3. Product Benchmarking
- 9.6.4. Recent Development
9.7. ICU Medical, Inc.
- 9.7.1. Company Overview
- 9.7.2. Financial Performance
- 9.7.3. Product Benchmarking
- 9.7.4. Recent Development
9.8. Integra LifeSciences Corporation
- 9.8.1. Company Overview
- 9.8.2. Financial Performance
- 9.8.3. Product Benchmarking
- 9.8.4. Recent Development
9.9. Medtronic, Inc.
- 9.9.1. Company Overview
- 9.9.2. Financial Performance
- 9.9.3. Product Benchmarking
- 9.9.4. Recent Development
9.10. Natus Medical Incorporated
- 9.10.1. Company Overview
- 9.10.2. Financial Performance
- 9.10.3. Product Benchmarking
- 9.10.4. Recent Development
9.11. Smiths Medical, Inc.
- 9.11.1. Company Overview
- 9.11.2. Financial Performance
- 9.11.3. Product Benchmarking
- 9.11.4. Recent Development
9.12. Stryker Corporation
- 9.12.1. Company Overview
- 9.12.2. Financial Performance
- 9.12.3. Product Benchmarking
- 9.12.4. Recent Development